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G q and its Aktions
David M. Harris, Andrea D. Eckhart and Walter J. Koch
Center for Translational Medicine, Department of Medicine, Thomas Jefferson
University, 1025 Walnut Street Room 317 Philadelphia, PA 19107, USA
_______________________________________________________________
Cardiovascular diseases remain the main cause of death in the western world. Many of
these diseases such as coronary artery disease, hypertension, and diabetes eventually lead
to chronic heart failure (HF). HF occurs when the heart cannot pump adequate blood to
meet metabolic demands. The primary initial response of cardiac myocytes to increased
work is a balance between hypertrophy and apoptosis, or programmed cell death.1,2
Apoptosis is thought to augment the progression to HF from compensatory hypertrophy
simply by decreasing the number of functional myocytes present in the heart.
Discovering what processes or pathways contribute to this tipping of the scale from
compensatory hypertrophy to HF remains a mystery and is paramount to helping treat HF
patients effectively.
It has been well documented that hypertrophy can be induced by endogenous and
exogenous agents that act on G protein-coupled receptors (GPCRs) that specifically
activate the heterotrimeric G protein Gq.1 Early pioneering studies showed that 71adrenergic receptor (71-AR) stimulation elicited hypertrophy in response to
norepinephrine (NE) in neonatal rat ventricular myocytes (NRVMs).3 Subsequently,
many other Gq-coupled receptor agonists have been shown to cause hypertrophy
including angiotensin II (AngII), endothelin-1 (ET-1), thrombin and prostaglandins. This
hypertrophy is considered to be compensatory at first, aiding the heart in maintaining
cardiac output and supplying needed oxygenated blood to distant organs. However, this
compensatory hypertrophy can become deleterious and the heart begins its slide into
failure. At what point the scale tips in favor of maladaptation and HF versus adaptive
cardiac hypertrophy is the research goal of many investigators and discovering molecules
or pathways that can act on both sides of this scale is essential in understanding the
transition to HF.
In this issue of the Journal of Molecular and Cellular Cardiology Howes et al.4 attempt
to separate cell survival from hypertrophy in response to direct G7q stimulation. The
authors demonstrate the ability of the 7-subunit of Gq to activate two separate
downstream pathways independently: hypertrophy and anti-apoptotic mechanisms. The
current manuscript suggests that direct G7q stimulation is a candidate that may play a
role in mediating a balance between these two pathways with the primary mechanistic
target the activation of Akt (also known as protein kinase B).
Numerous studies to date have demonstrated that GPCRs are important in activating the
phosphoinositide-3 kinase (PI3K)/Akt pathway, which is a cellular pro-survival signaling
axis. PI3K phosphorylates and activates Akt which subsequently phosphorylates
glycogen synthase-3? (GSK3?) inhibiting its apoptotic effects on NF-AT, ?-catenin and

caspase-3 activation.5 Upon activation of a given GPCR, its 7 subunit and ?@ subunits
dissociate and each component can activate a number of downstream molecules and
therefore, both could theoretically be involved in Akt activation. In vitro studies have
shown that both G7q and G?@ (from Gi-coupled receptors) can activate Akt.6 Recent in
vivo experiments have also shown the importance of G?@ activating the PI3K–Akt
pathway in the hypertrophying heart as transgenic mice expressing a G?@ sequestering
peptide (?ARKct) had significantly less activation of PI3K in myocardium after pressureoverload compared to non-transgenic control mice indicating that PI3K activation,
upstream of Akt activation, is ?@-subunit dependent.7 The current manuscript is important
as it clearly illustrates that G7q alone can activate Akt in a PI3K-dependent manner.
Future studies will need to be completed in order to verify that different combinations ?@
subunits, which may not be sequestered by the ?ARKct, are not involved.
In addition to their more classically appreciated signaling cascades, it is now appreciated
that GPCRs, including those that are Gq coupled such as AngII AT1 receptors, can also
activate PI3K via transactivation of receptor tyrosine kinases (RTKs) such as the receptor
for epidermal growth factor (EGFR).8 The pathophysiological significance of this novel
Akt signaling is not known but could be important especially in conditions of cardiac
stress. Moreover, it is not completely understood whether G7q alone can do this. Another
level of complexity is added when one considers that a given GPCR is capable of
coupling and activating multiple G proteins. Therefore, it has been difficult to definitely
and directly ascribe the role of individual G proteins in PI3K-mediated Akt activation or
whether this is RTK dependent. In this current study, overexpressed G7q alone is able to
activate the tyrosine kinase, Src, which phosphorylates and activates the EFGR and
causes PI3K-dependent Akt phosphorylation.4 The transactivation of the EGFR by G7q is
similar in mechanisms to the GPCR–RTK cross-talk that occurs in cardiac fibroblasts
where activation of ?2-ARs causes cell proliferation in an Src and EGFR-dependent
manner.9 The end result of G7q-Akt activation in Howes et al. [4] 4 is an increase in
cardiomyocyte survival when these cells are exposed to the pro-apoptotic agent, 2deoxyglucose (2DOG).
The premise that G7q can have cellular pro-survival features is intriguing considering
that initial studies ascribed G7q overexpression as a condition causing the heart to fail in
vivo and also inducing apoptosis after cardiac stress.10, 11 These studies in transgenic
mice also demonstrated a dose-dependent on G7q expression in cardiac hypertrophy and
pathology. Lower levels had minimal effects on cardiac growth while higher levels either
caused significance hypertrophy and HF or even death due to ventricular failure.10 This
finding led to further studies comparing wild-type G7q overexpression and
overexpression of a constitutively active mutated form of G7q (GqQ209L) in cardiac
myocytes.11 Data showed that although both wild-type G7q and GqQ209L caused
hypertrophy of cells, only the constitutively active GqQ209L produced apoptotic cell
death. Importantly, those studies and the current study within this issue may in fact be
complementary. Previously, it was shown that the constitutively active mutant GqQ209L
decreased levels of phosphatidylinositol bisphosphate (PIP2), a substrate for PI3K, thus
decreasing the ability of PI3K to activate Akt that occurs downstream.4 This depletion is
explained by the increased phospholipase C (PLC) activity caused by GqQ209L

expressing cells. Therefore, it was concluded that decreased levels of PIP2 due to
enhanced Gq activity in heart failure limit the availability of PIP2 for PI3K/Akt
signaling.4 The current manuscript by this group provides novel mechanistic insight into
how G7q overexpression activates Akt and provides anti-apoptotic effects, presumably in
conditions where PIP2 is not limiting.
Howes et al. provides evidence that not only can G7q mediate cardiac hypertrophy
through PKC and MAPK signaling, it can also directly signal via the cardioprotective
PI3K pathway. This manuscript is also one of the first to describe that Gq can transactive
the EGFR in a PKC- and Ca2+-independent manner, which is interesting since the
primary downstream actions of Gq-coupled GPCRs are tied to activation of
phospholipase C, PKC and Ca2+ mobilization.6 It will be interesting to investigate the
mechanisms underlying this novel signaling pathway of G7q and whether this is due to
specific spatial and temporal activation of Gq-coupled receptors in the myocyte.
Another important finding from this study is the ability to separate the hypertrophic
pathways stimulated by more classical Gq that are EGFR independent (MAPK and
calciuneurin) from the cardiomyocyte protective pathways that are dependent upon novel
G7q–EGFR activation.4 At which point activation of G7q prefers one pathway versus the
other raises an interesting question. In the early stages of cardiovascular disease it could
be hypothesized that there may be equal signaling down the respective hypertrophic and
the anti-apoptotic pathways in myocytes resulting in cardiac hypertrophy with adequate
function, as would occur with compensatory hypertrophy. In the chronic setting, as
circulating levels of AngII, ET-1, and NE increase and exposure is prolonged, activation
of Gq-coupled receptors increases, and the “stealing” of PIP2 by the hypertrophic
pathways may become prevalent resulting in a decrease in the ability of G7q to activate
the Src/EGFR dependent PI3K/Akt signaling cascade. With a subsequent decrease in
phosphorylated (i.e. activated) Akt (phospho-Akt) and its cardioprotective benefits, cell
survival would be compromised with a decrease in myocytes the ventricles will become
dysfunctional.
The dissection of these pathways provides valuable information on the mechanisms that
are associated with G7q stimulation. However, it is important to keep in mind that
although Gq signaling is increased through particular GPCRs in hypertrophy and HF, the
expression levels of G7q are not increased, unlike what has been shown for other G
proteins including G7i.12 In the current study, the authors wanted to investigate Gq
signaling specifically therefore used the overexpression strategy as they did not want to
complicate the results by adding a Gq-coupled agonist. As discussed above this is
important because many Gq-coupled receptors can couple to other G proteins such as Gi
or also can directly activate other proteins including ion channels and thus, the authors
chose to study “pure” G7q signaling. However, it is important that effects from these
confounding variables be considered within the context of Gq-coupled signaling in vivo
in the failing heart as you cannot have simple G7q activation without activation of a
GPCR and thus in HF there could be influences of other downstream signaling events
following Gq activation.

Another important variable that needs to be considered when examining signaling in
cardiac myocytes is the overall role of Ca2+ and electrical stimulation. Activated Gproteins interact with ion channels, transporters, and other signaling molecules located at
the membrane that may contribute to in vivo effects. Within the contracting
cardiomyocyte, there is a flux of Ca2+ into the cell initiating Ca2+ release from the
sarcoplasmic reticulum and this rapid elevation of intracellular Ca2+ is needed for
contraction of the myofilaments. Since some Gq-coupled receptors have been shown in
some cell types to transactivate the EGFR in a Ca2+-dependent manner13, Ca2+ becomes a
vital second messenger that may also contribute to effects similar to what Howes et al.
report and contribute to specific components of Gq signaling. Of importance here is that
this Ca2+-dependent EGFR transactivation has not yet been shown in myocytes. However,
Ca2+ is also important in heart disease since it can lead to the activation of Ca2+calmodulin kinase (CaMKII) and Ca2+-dependent PKC isozymes and this can complicate
downstream kinase signaling including Akt activation and directly assessing mechanisms.
Genetic approaches provide researchers with great tools in order to delineate signaling
pathways and observe the effects of targeted molecules on the system chosen. Instead of
using genetic approaches to study the effects of G7q activation, a recent paper by Sabri et
al.14 describes use of an intracellular G7q agonist (recombinant Pasteurella multocida
toxin (rPMT)) to elucidate the role of endogenous G7q signaling in NRVM. Activation of
NRVM with rPMT revealed that novel isoforms of PKC (M and N) were activated by
rPMT treatment but not the conventional PKC that is present in rat NRVM (PKC7). This
paper highlighted that following exposure to rPMT (endogenous G7q activation) for
24 hours, there is a decrease in the amount of phospho-Akt. There was also a small but
insignificant increase in apoptosis measured by TUNEL-positive cells when exposed to
H2O2, reinforcing the thought that cardioprotection is lost when the cells are activated
with rPMT. Further the study went to show that there was decreased phospho-Akt when
GF109203X (non-selective inhibitor of PKC 7, M, and N) was used in rPMT treated cells
implicating the novel PKC isoforms M and N in repression of Akt activation.14 In the
current manuscript by Howes et al., when the same inhibitor was used, there were no
alterations in phospho-Akt [4]. Since G7q signaling appears to be so reliant on the
amount of expression, differences in G7q levels could be responsible for the differences
observed. Also, the abundance or translocation of PKC isoforms could have been
different between the two studies. The physical location and compartmentalization of the
signaling molecules must also be considered since this plays a vital role in their ability to
activate other downstream molecules.
The differences in physiological versus pathological PI3K signaling could also be
responsible for the differences between studies. A recent review by Dorn and Force1
highlights the different isoforms of PI3K activated by the IP3 pathway (@) and that of the
IGF-1 (7) pathway. The activation of PI3K is different between these two pathways as
both rely on the p110 molecule for signaling but once again different isoforms are
associated with the two pathways: p110@ for Gq coupled receptor and p1107 for the
growth factor receptors. Interestingly, p1107 is responsible for physiological growth, and
is not needed for pathological growth whereas p110@ is opposite in mediating
pathological hypertrophy, but not exercise or physiological hypertrophy. Both PI3K

isoforms lead to Akt activation, however, it should be noted the Akt activation can lead to
both physiologic and pathologic growth through GSK3? and/or mTOR. The balance
between activation of G7q and EGFR, which PI3K isoform is activated and signaling
duration could all play a major role in the effects observed in the current paper.
Although Akt activation via G7q could prove to be beneficial in treating disease, it must
also be noted that inhibiting Gq signaling altogether has been shown to have beneficial
effects in the heart by attenuating hypertrophy and maladaptation following pressure
overload.15, 16 This was done with a peptide inhibitor of GPCR-G7q coupling and in
transgenic hearts expressing this peptide inhibitor of Gq, hypertrophy was attenuated
following transverse thoracic aorta constriction (TAC) and chronically this led to
preservation of cardiac function and prevention of maladaptive remodeling.16 G7q
inhibition has also proven to be successful in other tissues including vascular smooth
muscle where G7q inhibition attenuates hypertension induced by AngII.17 Moreover, the
success of clinical trials (LIFE18 and EUROPA19) showing improvements in LV
hypertrophy following treatment with Losartan (AngII receptor antagonist) and
perindopril (ACE inhibitor) also cannot be ignored since these drugs do decrease overall
Gq signaling in the cardiomyocyte. Thus, although G7q stimulation can lead to cell
survival, there is ample evidence that Gq inhibition is beneficial in HF
In summary, the current manuscript by Howes et al. in JMCC illustrates the ability of
G7q to directly activate two separate downstream pathways independently and initiate
two different effects: hypertrophy and cell survival via Akt activation that is dependent
on Src/EGFR/PI3K activation. The triggers that cause hearts in compensated hypertrophy
to progress into a state of cardiac failure are still unknown. The current manuscript offers
G7q as a candidate that may play a role in mediating this balance between pathways. It
also reminds us that multiple signaling pathways are continuously activated by any one
molecule and that dissecting out the specific pathways involved mechanistically may
provide novel targets for future HF therapies.
_________________________________________________________________
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